Wednesday, 16 May 2012

Sphingosine Kinase 1 inhibitors for treatment of cancer...

Cancer is one of the biggest killers world wide and it’s prevalence  is only set to increase due to the aging population and changes in lifestyle.

The major problem, in terms of successful treatment of cancer, is the development of chemotherapeutic resistance by the cancer cells  which results in unopposed metastasis of the cancer and ultimately death of the patient Now researchers at Strathclyde University have found that sphingosine kinase-1 (SK1) is present in high levels in the tumours of breast cancer patients. It has also been found to induce resistance in breast and androgen-independent prostate cancer cells. Both indicate that the enzyme may have a role in the generic development of resistance in cancer cells.

The team have synthesised inhibitors of SK1 and have also identified natural product inhibitors of the enzyme. Additional work is being done to map the allosteric sites of SK1 to inform the ongoing drug discovery programme. SK1 inhibitors also induce apoptosis of cancer cells, thereby providing an effective means to killing these cells.